Want to see ALVO full AI Analyst Report?
ALVO Stock Chart & Stats
$3.06
$0.02(0.65%)
At close: 4:00 PM EDT
$3.06
$0.02(0.65%)
Day’s Range― - ―
52-Week Range$2.94 - $9.25
Previous Close$3.08
Volume397.90K
Average Volume (3M)847.68K
Market Cap
$1.73B
Enterprise Value$2.63K
Total Cash (Recent Filing)$142.75M
Total Debt (Recent Filing)$1.45B
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 11, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding390,431,500
10 Day Avg. Volume655,921
30 Day Avg. Volume847,682
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-5.03
Price to Sales (P/S)2.44
P/FCF Ratio-12.49
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.67Price Target Upside85.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$621.81M
Bulls Say, Bears Say
Bulls Say
Broad Biosimilar Pipeline And Regulatory ProgressA broad pipeline diversifies future growth beyond current products, while complete BLA resubmissions and FDA review acceptance reduce regulatory uncertainty. Progress across several candidates can support recurring launches, partner economics and manufacturing utilization over multiple years.
Expanding Commercial Footprint And Partner ReachMultiple marketed products and geographic launches demonstrate commercialization capability and broaden access to revenue sources. The Lotus agreement adds distribution capacity in the United States and Asia while preserving Alvotech’s supply role and development control.
Strong Gross-margin Potential From Integrated ManufacturingThe combination of substantial revenue scale-up and strong gross margins indicates that Alvotech’s integrated development and manufacturing platform can produce attractive economics when supply is stable. Greater scale may improve fixed-cost absorption and support partner competitiveness.
Bears Say
Highly Leveraged Balance Sheet With Negative EquityHeavy debt and negative equity leave limited balance-sheet protection if operating results remain uneven. Refinancing needs, covenant pressure and restricted financial flexibility could constrain investment in the pipeline or require additional dilutive or costly funding.
Persistent Cash Burn And High Interest BurdenThe business is not currently self-funding, and substantial cash interest absorbs resources that could otherwise support R&D, launches or debt reduction. Continued negative cash generation increases dependence on external capital and heightens execution risk.
Revenue And Product Profitability Remain VolatileThe revenue decline and very low product margins show that manufacturing disruptions, partner ordering and milestone timing still materially affect performance. This volatility makes sustainable earnings harder to establish and could delay deleveraging even if Q4 improves.
Alvotech News
ALVO FAQ
What was Alvotech’s price range in the past 12 months?
Alvotech lowest stock price was $2.94 and its highest was $9.25 in the past 12 months.
What is Alvotech’s market cap?
Alvotech’s market cap is $1.73B.
When is Alvotech’s upcoming earnings report date?
Alvotech’s upcoming earnings report date is Nov 11, 2026 which is in 78 days.
How were Alvotech’s earnings last quarter?
Alvotech released its earnings results on Aug 19, 2026. The company reported -$0.092 earnings per share for the quarter, missing the consensus estimate of -$0.053 by -$0.039.
Is Alvotech overvalued?
According to Wall Street analysts Alvotech’s price is currently Undervalued.
Does Alvotech pay dividends?
Alvotech does not currently pay dividends.
What is Alvotech’s EPS estimate?
Alvotech’s EPS estimate is -0.02.
How many shares outstanding does Alvotech have?
Alvotech has 390,431,500 shares outstanding.
What happened to Alvotech’s price movement after its last earnings report?
Alvotech reported an EPS of -$0.092 in its last earnings report, missing expectations of -$0.053. Following the earnings report the stock price went up 7.018%.
Which hedge fund is a major shareholder of Alvotech?
Currently, no hedge funds are holding shares in ALVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alvotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.67 (85.19% Upside)
$5.67 (85.19% Upside)
Blogger Sentiment
Bullish
ALVO Sentiment 78%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
13.98%
Trailing 12-Months
Company Description
Alvotech
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
ALVO Company Deck
ALVO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational and regulatory progress (BLA resubmissions, FDA inspection closure, manufacturing recovery, pipeline breadth and successful financing) against material near‑term financial headwinds (a 31% decline in H1 revenue, lower adjusted EBITDA, compressed product margins, increased cash interest burdens and reliance on lumpy milestone revenue). Management reaffirmed 2026 guidance and expects a strong Q4 as supply normalizes, but near‑term results remain impacted by the prior manufacturing slowdown and timing of partner orders and milestones.View all ALVO earnings summariesALVO Stock 12 Month Forecast
Average Price Target
$5.67
▲(85.19% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
1.22% Mutual Funds
6.52% Other Institutional Investors
91.73% Public Companies and
Individual Investors